Moderate dose-intensive chemotherapy for patients with non-small cell lung cancer: randomized trial, can it improve survival of patients with good performance status?
| Autor: | Takashi Horie, Noriaki Takahashi, Masayuki Masutani, Ichiro Tsujino, Yamaguchi M, Kiyoko Miyagi, T. Fujie, Yoshiaki Koya, Takako Yano |
|---|---|
| Rok vydání: | 1999 |
| Předmět: |
Adult
Male Cancer Research medicine.medical_specialty Lung Neoplasms Vindesine Mitomycin medicine.medical_treatment Gastroenterology Carcinoma Non-Small-Cell Lung Internal medicine Antineoplastic Combined Chemotherapy Protocols Granulocyte Colony-Stimulating Factor parasitic diseases medicine Humans Lung cancer Survival analysis Aged Chemotherapy Performance status business.industry Mitomycin C General Medicine Middle Aged medicine.disease Survival Analysis Surgery Regimen Oncology Concomitant Female Cisplatin business medicine.drug |
| Zdroj: | Oncology Reports. |
| ISSN: | 1791-2431 1021-335X |
| DOI: | 10.3892/or.6.5.1045 |
| Popis: | Advanced non-small cell lung cancer (NSCLC) has proven to be remarkably resistant to standard chemotherapy regimens. One potential alternative approach is the use of dose-intensive chemotherapy with supportive therapy such as granulocyte-colony stimulating factor (G-CSF). We conducted a randomized study of dose-intensive cisplatin/vindesine/mitomycin C chemotherapy (DI-PVM) and standard cisplatin/vindesine/mitomycin C chemotherapy (PVM). A total of one hundred patients with III-IV NSCLC was randomized. The DI-PVM consisted of 3 cycles of cisplatin: 80 mg/m2 (day 1), vindesine: 3 mg/m2 (days 1 and 8) and mitomycin C: 8 mg/m2 (day 1) in 3-week intervals with concurrent G-CSF. The PVM consisted of 2 cycles of the same chemotherapy in 4-week intervals. Blood cell counts were checked twice a week, and G-CSF (2 microgram/kg, SC) was administered when the count was |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|